UCB S.A. (UCB.BR) stock analysis

In our weekly check, UCB S.A. is graded A (A to F). Of 25 checks on debt, profit, cash flow and trend: 21 pass, warnings: 2, red flags: 2.

About UCB S.A.

UCB S.A. is a Healthcare company (Biotechnology) based in Belgium, listed on BRU as UCB.BR.

What our checks show for UCB.BR

Red flags

• The stock has fallen as much as 62% from a peak. Would you have held through that?
• Recovering from its deepest fall took about 4.3 years.

Warning signs

• The price swings a lot: 38.9% annual volatility. Expect large ups and downs.
• Thinly traded (about 260 thousand shares a day): buying and selling can move the price.

Strengths

• Debt is low: 0.31x equity.
• Operating profit covers interest 10.2 times over.
• The net margin rose by 1.8 points over 5 years, to 20.1%.
• Operating cash flow is 1.39x net profit: the profit arrives as real cash.
• Analysts expect earnings per share to grow about 26% a year over the next years.
• Analysts expect the net margin to improve by 9.2 points from today's 20.1%.

Similar companies

ARGX · LONN.SW · ONC · RVMD · 1548.HK · 9926.HK

Questions

What grade does UCB S.A. (UCB.BR) have?

In our weekly check, UCB S.A. is graded A (A to F). Of 25 checks on debt, profit, cash flow and trend: 21 pass, warnings: 2, red flags: 2. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of UCB.BR stock?

This week's biggest flags for UCB S.A.: Deep past fall, Slow recovery after falls, Very volatile. In total 4 of 25 checks show a warning or a red flag.

What does UCB S.A. do?

UCB S.A. is a Healthcare company (Biotechnology) based in Belgium, listed on BRU as UCB.BR.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-24

Open the full analysis